One Health Group A Healthy Investment Opportunity say Panmure Liberum

One Health Group
[shareaholic app="share_buttons" id_name="post_below_content"]

Panmure Liberum’s latest research, led by healthcare analyst Seb Jantet, highlights One Health Group Plc (AQSE:OHGR) as a standout player in the UK healthcare sector, focused on delivering NHS-funded surgical procedures to underserved regions. This strategic approach not only aligns with NHS goals but positions One Health Group as a significant partner in tackling the NHS backlog. With a “Buy” rating and an optimistic target price of 275p, Panmure Liberum underscores One Health’s potential for sustained growth.

Strategic Model Aligned with NHS Needs

Operating primarily in the Midlands and the North of England, One Health Group brings critical surgical procedures in orthopaedics, spine, gynaecology, and general surgery to areas with limited NHS infrastructure. Through 37 community-based clinics and partnerships with independent surgical sites, the group efficiently channels patients through consultations and follow-ups near their homes, with surgeries held at the closest partnered hospitals. “One Health brings NHS capacity to underserved areas,” Jantet explains, noting how their model alleviates waiting lists where demand is greatest.

Growing Patient Access and Positive Market Conditions

One Health Group’s approach also benefits patients by providing shorter wait times – typically around eight weeks versus the NHS average of 20 weeks in some areas. This appeal has led to a consistent increase in procedures performed, with a compound annual growth rate of 12% over the last two years. Jantet’s report points to the efficiency of One Health’s liaison team, which guides patients from consultation through recovery, resulting in a smooth experience that has yielded patient satisfaction scores above 99%.

Scaling through Surgical Hubs for Robust Growth

Looking ahead, One Health aims to open proprietary surgical hubs, which could add an estimated £6 million in revenue per site. With a potential return on investment (ROI) of 10-17%, this expansion is set to “supercharge growth,” according to Jantet. Each hub is designed to address local demand and draw on One Health’s established patient and consultant network, optimising patient outcomes while increasing EBITDA margins to nearly 20%.

A Bright Financial Future

Financially, One Health’s growth prospects are equally compelling. With its current asset-light model, the group has achieved a 15% revenue CAGR over the past two years. Panmure Liberum forecasts suggest that revenue growth will remain strong at 10% CAGR in the coming years. However, if surgical hubs perform as projected, EBITDA growth could double, giving One Health a significant earnings boost.

In Closing

One Health Group’s efficient NHS-aligned model, geographic focus on underserved regions, and plans for surgical hub expansion all point towards a promising investment trajectory. Analyst Seb Jantet affirms, “Shares are cheap in absolute terms and vs closest comparators,” adding that potential developments like a renewed Independent Sector Treatment Centre (ISTC) programme could be “transformative” for the company. With a Buy rating and strong fundamentals, One Health Group is well-positioned to support the NHS and drive value for investors.

Share on:
Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:
    Discover One Health Group's innovative approach to back and spine care, blending advanced surgeries with non-invasive therapies for optimal patient outcomes.
    One Health Group is set to transform orthopaedic care in the North of England with its first surgical hub, enhancing patient access to essential NHS services.
    Under CEO Adam Binns, One Health Group has revolutionized healthcare through innovation, talent development, and strategic growth, achieving remarkable financial success.
    One Health Group plc has exchanged contracts to acquire land for its first Surgical Hub in Northern England, with planning approval anticipated soon.
    One Health Group Plc's recent AIM admission and £7.8 million funding raise mark a pivotal moment. CEO Adam Binns shares insights into growth strategies and NHS support.
    CEO Adam Binns outlines how this funding milestone unlocks the development of high-efficiency surgical hubs in under-served UK regions

    Search

    Search